

Brussels, 22 April 2026
(OR. en)

8394/26

SAN 234
PHARM 65
MI 368
DELECT 73

COVER NOTE

From: Secretary-General of the European Commission, signed by Ms Martine DEPREZ, Director

date of receipt: 20 April 2026

To: Ms Thérèse BLANCHET, Secretary-General of the Council of the European Union

No. Cion doc.: C(2026) 2491 final

Subject: COMMISSION DELEGATED REGULATION (EU) .../... correcting certain language versions of Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use

Delegations will find attached document C(2026) 2491 final.

Encl.: C(2026) 2491 final



Brussels, 20.4.2026
C(2026) 2491 final

COMMISSION DELEGATED REGULATION (EU) .../...

of 20.4.2026

**correcting certain language versions of Regulation (EC) No 1234/2008 concerning the
examination of variations to the terms of marketing authorisations for medicinal
products for human use**

(Text with EEA relevance)

EXPLANATORY MEMORANDUM

1. CONTEXT OF THE DELEGATED ACT

The Bulgarian, Dutch, Estonian, Greek, Lithuanian and Polish language versions of Regulation (EC) No 1234/2008 contain an error. In order to align those language versions with the other language versions, a Delegated Regulation correcting Regulation (EC) No 1234/2008 needs to be adopted.

2. LEGAL ELEMENTS OF THE DELEGATED ACT

This Delegated Regulation corrects a translation error in the Bulgarian, Dutch, Estonian, Greek, Lithuanian and Polish language versions of the text.

COMMISSION DELEGATED REGULATION (EU) .../...

of 20.4.2026

correcting certain language versions of Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use¹, and in particular Article 23b(2a) thereof,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency², and in particular Article 16a(3) thereof,

Whereas:

- (1) The Bulgarian, Dutch, Estonian, Greek, Lithuanian and Polish language versions of Commission Regulation (EC) No 1234/2008³ contain an error in Article 20(1), as regards the legal obligation of the marketing authorisation holder to follow the worksharing procedure laid down in paragraphs 3 to 9 of that Article. The error alters the meaning of the provision, affecting its substance.
- (2) The Bulgarian, Dutch, Estonian, Greek, Lithuanian and Polish language versions of Regulation (EC) No 1234/2008 should therefore be corrected accordingly. The other language versions are not affected,

HAS ADOPTED THIS REGULATION:

Article 1

(does not concern the English language)

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

¹ OJ L 311, 28.11.2001, p. 67, ELI: <http://data.europa.eu/eli/dir/2001/83/oj>.

² OJ L 136, 30.4.2004, p. 1, ELI: <http://data.europa.eu/eli/reg/2004/726/oj>.

³ Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use (OJ L 334, 12.12.2008, p. 7, ELI: <http://data.europa.eu/eli/reg/2008/1234/oj>).

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 20.4.2026

For the Commission
The President
Ursula VON DER LEYEN